Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs)Its proprietary ADC technology opens the door

Related Keywords

Milan ,Lombardia ,Italy ,Paris ,France General ,France ,London ,City Of ,United Kingdom ,Jean Guillaume Lafay ,Fondation Fournier Majoie ,Mablink Adcs ,Graziano Seghezzi ,Alpha Fra ,Mablink Bioscience ,Kostenloser Wertpapierhandel ,Florian Denis ,Europe Venture Fund ,Sofinnova Partners ,Equity Partners ,Chief Executive Officer ,Managing Partner ,Pertinence Invest ,Investment Director ,Elaia Partners ,Sham Innovation Sant ,Turenne Capital ,Simba Sant ,Folate Receptor Alpha ,Venture Capital ,Venture Fund ,Mablink ,Ioscience ,Nnounces ,Billion ,Series ,Funding ,Hound ,Sofinnova ,Partners ,M 233 Rieux ,Equity ,